Home The Word Brain Fast Track My Amedeo FAQ About Flying Publisher   

Fast Track

Ear2MemoryFree App | Free PDF | Web
Learning languages on your smartphone
By BSK

Free Abstracts

  Venous Thrombosis

  Free Subscription


Articles published in Thromb Haemost

Retrieve available abstracts of 76 articles:
HTML format
Text format



Single Articles


    May 2017
  1. CHUNG WS, Lin CL
    Increased risks of venous thromboembolism in patients with psoriasis. A Nationwide Cohort Study.
    Thromb Haemost. 2017 May 24. doi: 10.1160/TH17-01-0039.
    PubMed     Text format     Abstract available


    April 2017
  2. SANTI RM, Ceccarelli M, Bernocco E, Monagheddu C, et al
    Khorana score and histotype predicts incidence of early venous thromboembolism in non-Hodgkin lymphomas. A pooled-data analysis of 12 clinical trials of Fondazione Italiana Linfomi (FIL).
    Thromb Haemost. 2017 Apr 27. doi: 10.1160/TH16-11-0895.
    PubMed     Text format     Abstract available


  3. SCHULMAN S, Singer D, Ageno W, Casella IB, et al
    NOACs for treatment of venous thromboembolism in clinical practice.
    Thromb Haemost. 2017 Apr 20. doi: 10.1160/TH17-01-0065.
    PubMed     Text format     Abstract available


  4. COHEN AT, Gitt AK, Bauersachs R, Fronk EM, et al
    The management of acute venous thromboembolism in clinical practice. Results from the European PREFER in VTE Registry.
    Thromb Haemost. 2017 Apr 13. doi: 10.1160/TH16-10-0793.
    PubMed     Text format     Abstract available


    March 2017
  5. RAJPURKAR M, Biss T, Amankwah E, Martinez D, et al
    Pulmonary embolism and in situ pulmonary artery thrombosis in paediatrics. A systematic review.
    Thromb Haemost. 2017 Mar 23. doi: 10.1160/TH16-07-0529.
    PubMed     Text format     Abstract available


  6. SINDET-PEDERSEN C, Langtved Pallisgaard J, Staerk L, Gerds TA, et al
    Comparative safety and effectiveness of rivaroxaban versus VKAs in patients with venous thromboembolism. A Danish nationwide registry-based study.
    Thromb Haemost. 2017 Mar 16. doi: 10.1160/TH16-10-0745.
    PubMed     Text format     Abstract available


  7. TAFUR AJ, Caprini JA, Cote L, Trujillo-Santos J, et al
    Predictors of active cancer thromboembolic outcomes. RIETE experience of the Khorana score in cancer-associated thrombosis.
    Thromb Haemost. 2017 Mar 9. doi: 10.1160/TH16-11-0840.
    PubMed     Text format     Abstract available


  8. KLOK FA, Barco S, Konstantinides SV
    External validation of the VTE-BLEED score for predicting major bleeding in stable anticoagulated patients with venous thromboembolism.
    Thromb Haemost. 2017 Mar 9. doi: 10.1160/TH16-10-0810.
    PubMed     Text format     Abstract available


    February 2017

  9. Erratum to Heit et al. "Reasons for the persistent incidence of venous thromboembolism" (Thromb Haemost 2017; 117: 390-400).
    Thromb Haemost. 2017;117:643.
    PubMed     Text format    


  10. HEIT JA, Armasu SM, McCauley BM, Kullo IJ, et al
    Identification of unique venous thromboembolism-susceptibility variants in African-Americans.
    Thromb Haemost. 2017 Feb 16. doi: 10.1160/TH16-08-0652.
    PubMed     Text format     Abstract available


  11. BREKELMANS MP, Scheres LJ, Bleker SM, Hutten BA, et al
    Abnormal vaginal bleeding in women with venous thromboembolism treated with apixaban or warfarin.
    Thromb Haemost. 2017 Feb 9. doi: 10.1160/TH16-11-0874.
    PubMed     Text format     Abstract available


  12. STUCK AK, Spirk D, Schaudt J, Kucher N, et al
    Risk assessment models for venous thromboembolism in acutely ill medical patients. A systematic review.
    Thromb Haemost. 2017 Feb 2. doi: 10.1160/TH16-08-0631.
    PubMed     Text format     Abstract available


  13. BOCHENEK ML, Rosinus NS, Lankeit M, Hobohm L, et al
    From thrombosis to fibrosis in chronic thromboembolic pulmonary hypertension.
    Thromb Haemost. 2017 Feb 2. doi: 10.1160/TH16-10-0790.
    PubMed     Text format     Abstract available


    January 2017
  14. CHAI-ADISAKSOPHA C, Linkins LA, ALKindi SY, Cheah M, et al
    Outcomes of low-molecular-weight heparin treatment for venous thromboembolism in patients with primary and metastatic brain tumours.
    Thromb Haemost. 2017 Jan 12. doi: 10.1160/TH16-09-0680.
    PubMed     Text format     Abstract available


    December 2016
  15. HEIT JA, Ashrani A, Crusan DJ, McBane RD, et al
    Reasons for the persistent incidence of venous thromboembolism.
    Thromb Haemost. 2016.
    PubMed     Text format     Abstract available


    November 2016
  16. CHATTERJEE S, Weinberg I, Yeh RW, Chakraborty A, et al
    Risk factors for intracranial haemorrhage in patients with pulmonary embolism treated with thrombolytic therapy Development of the PE-CH Score.
    Thromb Haemost. 2016.
    PubMed     Text format     Abstract available


  17. AY C, Pabinger I, Cohen AT
    Cancer-associated venous thromboembolism: Burden, mechanisms, and management.
    Thromb Haemost. 2016.
    PubMed     Text format     Abstract available


  18. AGENO W, Casella I, Han CK, Raskob GE, et al
    RE-COVERY DVT/PE: Rationale and design of a prospective observational study of acute venous thromboembolism with a focus on dabigatran etexilate.
    Thromb Haemost. 2016.
    PubMed     Text format     Abstract available


    October 2016
  19. TRUJILLO-SANTOS J, Di Micco P, Dentali F, Douketis J, et al
    Real-life treatment of venous thromboembolism with direct oral anticoagulants: The influence of recommended dosing and regimens.
    Thromb Haemost. 2016.
    PubMed     Text format     Abstract available


  20. RIEDL J, Kaider A, Marosi C, Prager GW, et al
    Decreased platelet reactivity in patients with cancer is associated with high risk of venous thromboembolism and poor prognosis.
    Thromb Haemost. 2016;117.
    PubMed     Text format     Abstract available


  21. AMBROSINO P, Tarantino L, Di Minno G, Paternoster M, et al
    The risk of venous thromboembolism in patients with cirrhosis. A systematic review and meta-analysis.
    Thromb Haemost. 2016;117.
    PubMed     Text format     Abstract available



  22. Venous thromboembolism: A Call for risk assessment in all hospitalised patients.
    Thromb Haemost. 2016;116:777-779.
    PubMed     Text format    


  23. COHEN AT, Katholing A, Rietbrock S, Bamber L, et al
    Epidemiology of first and recurrent venous thromboembolism in patients with active cancer. A population-based cohort study.
    Thromb Haemost. 2016;117.
    PubMed     Text format     Abstract available


    September 2016

  24. Erratum to Barco et al. "Home treatment of patients with lowrisk pulmonary embolism with the oral factor Xa inhibitor rivaroxaban. Rationale and design of the Hot-PE Trial" (Thromb Haemost 2016; 116: 191-197).
    Thromb Haemost. 2016;116:775.
    PubMed     Text format     Abstract available


  25. WEITZ JI, Haas S, Ageno W, Angchaisuksiri P, et al
    Global Anticoagulant Registry in the Field - Venous Thromboembolism (GARFIELD-VTE). Rationale and design.
    Thromb Haemost. 2016;116.
    PubMed     Text format     Abstract available


  26. CAPPATO R, Welsh R
    Exploring unmet needs in venous and arterial thromboembolism with rivaroxaban.
    Thromb Haemost. 2016;116.
    PubMed     Text format     Abstract available


  27. BLEKER SM, Cohen AT, Buller HR, Agnelli G, et al
    Clinical presentation and course of bleeding events in patients with venous thromboembolism, treated with apixaban or enoxaparin and warfarin. Results from the AMPLIFY trial.
    Thromb Haemost. 2016;116.
    PubMed     Text format     Abstract available


    August 2016
  28. DI NISIO M, Vedovati MC, Riera-Mestre A, Prins MH, et al
    Treatment of venous thromboembolism with rivaroxaban in relation to body weight. A sub-analysis of the EINSTEIN DVT/PE studies.
    Thromb Haemost. 2016;116.
    PubMed     Text format     Abstract available


    July 2016
  29. DELLUC A, Tromeur C, Le Ven F, Gouillou M, et al
    Current incidence of venous thromboembolism and comparison with 1998: a community-based study in Western France.
    Thromb Haemost. 2016;116.
    PubMed     Text format     Abstract available


  30. VERHAMME P, Wells PS, Segers A, Ageno W, et al
    Dose reduction of edoxaban preserves efficacy and safety for the treatment of venous thromboembolism. An analysis of the randomised, double-blind HOKUSAI VTE trial.
    Thromb Haemost. 2016;116.
    PubMed     Text format     Abstract available


  31. ROLDAN V, Marin F
    Assessment of bleeding risk in acute ill medical patients. An essential part of venous thromboembolism prevention.
    Thromb Haemost. 2016;116.
    PubMed     Text format    


  32. GOLDHABER SZ, Schellong S, Kakkar A, Eriksson H, et al
    Treatment of acute pulmonary embolism with dabigatran versus warfarin. A pooled analysis of data from RE-COVER and RE-COVER II.
    Thromb Haemost. 2016;116.
    PubMed     Text format     Abstract available


  33. AMBROSINO P, Tarantino L, Criscuolo L, Nasto A, et al
    The risk of venous thromboembolism in patients with hepatitis C. A systematic review and meta-analysis.
    Thromb Haemost. 2016;116.
    PubMed     Text format     Abstract available


  34. NAGLER M, Kremer Hovinga JA, Alberio L, Peter-Salonen K, et al
    Thromboembolism in patients with congenital afibrinogenaemia. Long-term observational data and systematic review.
    Thromb Haemost. 2016;116.
    PubMed     Text format     Abstract available


    June 2016
  35. LUBBERTS B, Paulino Pereira NR, Kabrhel C, Kuter DJ, et al
    What is the effect of venous thromboembolism and related complications on patient reported health-related quality of life? A meta-analysis.
    Thromb Haemost. 2016;116.
    PubMed     Text format     Abstract available


  36. KUCHER N, Aujesky D, Beer JH, Mazzolai L, et al
    Rivaroxaban for the treatment of venous thromboembolism. The SWIss Venous ThromboEmbolism Registry (SWIVTER).
    Thromb Haemost. 2016;116.
    PubMed     Text format     Abstract available


  37. KITTELSON JM, Steg PG, Halperin JL, Goldenberg NA, et al
    Bivariate evaluation of thromboembolism and bleeding in clinical trials of anticoagulants in patients with atrial fibrillation.
    Thromb Haemost. 2016;116.
    PubMed     Text format     Abstract available


  38. CROUS-BOU M, De Vivo I, Camargo CA Jr, Varraso R, et al
    Interactions of established risk factors and a GWAS-based genetic risk score on the risk of venous thromboembolism.
    Thromb Haemost. 2016;116.
    PubMed     Text format     Abstract available


  39. AHMAD A, Sundquist K, Zoller B, Dahlback B, et al
    Identification of polymorphisms in Apolipoprotein M gene and their relationship with risk of recurrent venous thromboembolism.
    Thromb Haemost. 2016;116.
    PubMed     Text format     Abstract available


  40. LARSEN TB, Skjoth F, Grove EL, Nielsen PB, et al
    Effectiveness of self-managed oral anticoagulant therapy in patients with recurrent venous thromboembolism. A propensity-matched cohort study.
    Thromb Haemost. 2016;116.
    PubMed     Text format     Abstract available


    April 2016
  41. MANCO-JOHNSON MJ, Bomgaars L, Palascak J, Shapiro A, et al
    Efficacy and safety of protein C concentrate to treat purpura fulminans and thromboembolic events in severe congenital protein C deficiency.
    Thromb Haemost. 2016;116.
    PubMed     Text format     Abstract available


    March 2016
  42. BARCO S, Lankeit M, Binder H, Schellong S, et al
    Home treatment of patients with low-risk pulmonary embolism with the oral factor Xa inhibitor rivaroxaban. Rationale and design of the HoT-PE Trial.
    Thromb Haemost. 2016;116.
    PubMed     Text format     Abstract available


  43. WANG MT, Liou JT, Huang YW, Lin CW, et al
    Use of antipsychotics and risk of venous thromboembolism in postmenopausal women. A population-based nested case-control study.
    Thromb Haemost. 2016;115.
    PubMed     Text format     Abstract available


    February 2016
  44. PHILIPPART R, Brunet-Bernard A, Clementy N, Bourguignon T, et al
    Oral anticoagulation, stroke and thromboembolism in patients with atrial fibrillation and valve bioprosthesis. The Loire Valley Atrial Fibrillation Project.
    Thromb Haemost. 2016;115.
    PubMed     Text format     Abstract available


  45. WONG CC, Ng AC, Lau JK, Chow V, et al
    High mortality in patients presenting with acute pulmonary embolism and elevated INR not on anticoagulant therapy.
    Thromb Haemost. 2016;115.
    PubMed     Text format     Abstract available


    January 2016
  46. JIMENEZ D, Lobo JL, Fernandez-Golfin C, Portillo AK, et al
    Effectiveness of prognosticating pulmonary embolism using the ESC algorithm and the Bova score.
    Thromb Haemost. 2016;115.
    PubMed     Text format     Abstract available


  47. POSCH F, Riedl J, Reitter EM, Kaider A, et al
    Hypercoagulabilty, venous thromboembolism, and death in patients with cancer. A Multi-State Model.
    Thromb Haemost. 2016;115.
    PubMed     Text format     Abstract available


    December 2015
  48. RASKOB GE, Gallus AS, Sanders P, Thompson JR, et al
    Early time courses of recurrent thromboembolism and bleeding during apixaban or enoxaparin/warfarin therapy. A sub-analysis of the AMPLIFY trial.
    Thromb Haemost. 2015;115.
    PubMed     Text format     Abstract available


  49. BRATEANU A, Patel K, Chagin K, Tunsupon P, et al
    Probability of developing proximal deep-vein thrombosis and/or pulmonary embolism after distal deep-vein thrombosis.
    Thromb Haemost. 2015;115.
    PubMed     Text format     Abstract available


  50. KONSTANTINIDES SV
    Trends in incidence versus case fatality rates of pulmonary embolism: Good news or bad news?
    Thromb Haemost. 2015;115.
    PubMed     Text format    


    November 2015
  51. BARCO S, Woersching AL, Spyropoulos AC, Piovella F, et al
    European Union-28: An annualised cost-of-illness model for venous thromboembolism.
    Thromb Haemost. 2015;115.
    PubMed     Text format     Abstract available


  52. ANDRO M, Delluc A, Moineau MP, Tromeur C, et al
    Serum levels of 25(OH)D are not associated with venous thromboembolism in the elderly population. A case-control study.
    Thromb Haemost. 2015;115.
    PubMed     Text format     Abstract available


    October 2015
  53. DI NISIO M, Ageno W, Rutjes AW, Pap AF, et al
    Risk of major bleeding in patients with venous thromboembolism treated with rivaroxaban or with heparin and vitamin K antagonists.
    Thromb Haemost. 2015;115.
    PubMed     Text format     Abstract available


  54. ENGSTROM G, Zoller B, Svensson PJ, Melander O, et al
    Soluble urokinase plasminogen activator receptor and incidence of venous thromboembolism.
    Thromb Haemost. 2015;115.
    PubMed     Text format     Abstract available


  55. LIU X, Thompson J, Phatak H, Mardekian J, et al
    Extended anticoagulation with apixaban reduces hospitalisations in patients with venous thromboembolism. An analysis of the AMPLIFY-EXT trial.
    Thromb Haemost. 2015;115.
    PubMed     Text format     Abstract available


  56. CUNHA ML, Meijers JC, Middeldorp S
    Introduction to the analysis of next generation sequencing data and its application to venous thromboembolism.
    Thromb Haemost. 2015;114.
    PubMed     Text format     Abstract available


    September 2015
  57. MAJEED A, Goldhaber SZ, Kakkar A, Kearon C, et al
    Bleeding events with dabigatran or warfarin in patients with venous thromboembolism.
    Thromb Haemost. 2015;115.
    PubMed     Text format     Abstract available


  58. DENTALI F, Ageno W, Pomero F, Fenoglio L, et al
    Time trends and case fatality rate of in-hospital treated pulmonary embolism during 11 years of observation in Northwestern Italy.
    Thromb Haemost. 2015;115.
    PubMed     Text format     Abstract available


  59. LIN JN, Chen HJ, Lin MC, Lai CH, et al
    Risk of venous thromboembolism in patients with splenic injury and splenectomy. A nationwide cohort study.
    Thromb Haemost. 2015;115.
    PubMed     Text format     Abstract available


    August 2015
  60. IANOTTO JC, Chauveau A, Luque Paz D, Delluc A, et al
    Absence of CALR mutation among a cohort of 394 unselected patients with a first episode of unprovoked venous thromboembolism.
    Thromb Haemost. 2015;114.
    PubMed     Text format    


  61. SUCHON P, Al Frouh F, Henneuse A, Ibrahim M, et al
    Risk factors for venous thromboembolism in women under combined oral contraceptive. The PILl Genetic Risk Monitoring (PILGRIM) Study.
    Thromb Haemost. 2015;114.
    PubMed     Text format     Abstract available


  62. CHUNG WS, Lin CL, Kao CH
    Diabetesincreases the risk of deep-vein thrombosis and pulmonary embolism. A population-based cohort study.
    Thromb Haemost. 2015;114.
    PubMed     Text format     Abstract available


  63. VAN ES N, Di Nisio M, Bleker SM, Segers A, et al
    Edoxaban for treatment of venous thromboembolism in patients with cancer. Rationale and design of the Hokusai VTE-cancer study.
    Thromb Haemost. 2015;114.
    PubMed     Text format     Abstract available


  64. ZOLLER B, Li X, Ohlsson H, Ji J, et al
    Family history of venous thromboembolism as a risk factor and genetic research tool.
    Thromb Haemost. 2015;114.
    PubMed     Text format     Abstract available


  65. CUGNO M, Marzano AV, Bucciarelli P, Balice Y, et al
    Increased risk of venous thromboembolism in patients with bullous pemphigoid. The INVENTEP (INcidence of VENous ThromboEmbolism in bullous Pemphigoid) study.
    Thromb Haemost. 2015;114.
    PubMed     Text format     Abstract available


    July 2015
  66. KOOISTRA HA, Gebel M, Sahin K, Lensing AW, et al
    Independent predictors of poor vitamin K antagonist control in venous thromboembolism patients. Data from the EINSTEIN-DVT and PE studies.
    Thromb Haemost. 2015;114.
    PubMed     Text format     Abstract available


  67. TANG L, Hu Y
    Ethnic diversity in the genetics of venous thromboembolism.
    Thromb Haemost. 2015;114.
    PubMed     Text format     Abstract available


    June 2015
  68. BLACK SA, Cohen AT
    Anticoagulation strategies for venous thromboembolism: moving towards a personalised approach.
    Thromb Haemost. 2015;114.
    PubMed     Text format     Abstract available


  69. HILLIS C, Crowther MA
    Acute phase treatment of VTE: Anticoagulation, including non-vitamin K antagonist oral anticoagulants.
    Thromb Haemost. 2015;113:1193-202.
    PubMed     Text format     Abstract available


  70. GRANZIERA S, Cohen AT
    VTE primary prevention, including hospitalised medical and orthopaedic surgical patients.
    Thromb Haemost. 2015;113:1216-23.
    PubMed     Text format     Abstract available


  71. PRANDONI P, Barbar S, Milan M, Campello E, et al
    Optimal duration of anticoagulation. Provoked versus unprovoked VTE and role of adjunctive thrombophilia and imaging tests.
    Thromb Haemost. 2015;113:1210-5.
    PubMed     Text format     Abstract available


    May 2015
  72. CHAI-ADISAKSOPHA C, Hillis C, Monreal M, Witt DM, et al
    Thromboembolic events, recurrent bleeding and mortality after resuming anticoagulant following gastrointestinal bleeding. A meta-analysis.
    Thromb Haemost. 2015;114.
    PubMed     Text format     Abstract available


  73. DEN EXTER PL, van Es J, Kroft LJ, Erkens PM, et al
    Thromboembolic resolution assessed by CT pulmonary angiography after treatment for acute pulmonary embolism.
    Thromb Haemost. 2015;114.
    PubMed     Text format     Abstract available


  74. LIPPI G, Mattiuzzi C, Franchini M
    Sleep apnea and venous thromboembolism. A systematic review.
    Thromb Haemost. 2015;114.
    PubMed     Text format     Abstract available


  75. WEITZ JI, Bauersachs R, Beyer-Westendorf J, Bounameaux H, et al
    Two doses of rivaroxaban versus aspirin for prevention of recurrent venous thromboembolism. Rationale for and design of the EINSTEIN CHOICE study.
    Thromb Haemost. 2015;114.
    PubMed     Text format     Abstract available


  76. BASILI S, Proietti M, Perticone F, Corazza GR, et al
    Atrial fibrillation is not associated with increased risk of venous thromboembolism: Results from ARAPACIS study.
    Thromb Haemost. 2015;114.
    PubMed     Text format    


Thank you for your interest in scientific medicine.


AMEDEO Venous Thrombosis is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: